Abstract
Objective
To describe the pharmacokinetics of pregabalin in normal dogs after a single oral
dose.
Study design
Prospective experiment.
Animals
Six adult Labrador/Greyhound dogs (four females and two males) aged 2.6 (2.6–5.6)
years old (median and range) weighing 33.4 (26.8–42.1) kg.
Methods
After jugular vein catheterization, the dogs received a single oral dose of pregabalin
(∼4 mg kg−1). Blood samples were collected at: 0 (before drug administration), 15 and 30 minutes
and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 hours after drug administration. Plasma
pregabalin concentration was measured by HPLC. Noncompartmental analysis was used
to estimate pharmacokinetic variables.
Results
No adverse effects were observed. The median (range) pharmacokinetic parameters were:
Area under the curve from time 0 to 36 hours = 81.8 (56.5–92.1) μg hour mL−1; absorption half-life = 0.38 (0.25–1.11) hours; elimination half-life = 6.90 (6.21–7.40)
hours; time over 2.8 μg mL−1 (the presumed minimal effective concentration) = 11.11 (6.97–14.47) hours; maximal
plasma concentration (Cmax) = 7.15 (4.6–7.9) μg mL−1; time for Cmax to occur = 1.5 (1.0–4.0) hours. Assuming an 8-hour dosing interval, predicted minimal,
average, and maximal steady state plasma concentrations were 6.5 (4.8–8.1), 8.8 (7.3–10.9),
and 13.0 (8.8–15.2) μg mL−1. The corresponding values assuming a 12-hour interval were 3.8 (2.4–4.8), 6.8 (4.9–7.9),
and 10.1 (6.6–11.6) μg mL−1.
Conclusions and clinical relevance
Pregabalin 4 mg kg−1 PO produces plasma concentrations within the extrapolated therapeutic range from
humans for sufficient time to suggest that a twice daily dosing regime would be adequate.
Further study of the drug's safety and efficacy for the treatment of neuropathic pain
and seizures in dogs is warranted.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Veterinary Anaesthesia and AnalgesiaAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Absorption kinetics and bioavailability of phenobarbital after oral administration to dogs.J Vet Pharmacol Ther. 1985; 8: 205-207
- Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.Epilepsia. 2004; 45: 20-27
- Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.J Med Chem. 2005; 48: 2294-2307
- Pregabalin pharmacology and its relevance to clinical practice.Epilepsia. 2004; 45: 13-18
- Pregabalin and epilepsy.in: Shorvon S Fish D Dodson W Treatment of Epilepsy. 2nd edn. Blackwell Publishing Ltd, Oxford, UK2005: 469-499
- Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC.Ther Drug Monit. 2005; 27: 451-456
- Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.Neurology. 2005; 4: 475-480
- Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).Epilepsy Res. 2004; 261: 1-48
- Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies.Neurology. 2000; 54: A421
Bockbrader HN, Wesche DL (2004). Pharmacokinetic profile of pregabalin: results of a series of studies. Presented at the Annual Meeting of the American Psychiatric Association (abstract).
- Population pharmacokinetic (PK) analysis of pregabalin (PGB) in adult patients with refractory partial seizures.Epilepsia. 2001; 42 (abstract).: 84
- Population pharmacokinetic (PK) analyses of commonly prescribed antiepileptic drugs (AEDs) coadministered with pregabalin (PGB) in adult patients with refractory partial seizures.Epilepsia. 2001; 42 (abstract).: 84
- Drug interaction studies of pregabalin (CI-1008, PGB) in patients with epilepsy maintained on either valproate (VPA), lamotrigine (LTG), phenytoin (PHT), or carbamazepine (CBZ).Epilepsia. 2001; 42 (abstract).: 86
- 3-substituted GABA analogs with central nervous system activity: a review.Med Res Rev. 1999; 19: 149-177
- Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses.Epilepsia. 1998; 39 (abstract).: 58
- Metabolic disposition of pregabalin in healthy volunteers.Clin Pharmacol Ther. 2001; 69 (abstract).: 18
- Population pharmacokinetics of pregabalin in healthy volunteers, renally impaired patients and patients with chronic pain.J Pain. 2002; 3: 47
- Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro.Eur J Neurosci. 2004; 20: 1566-1576
- Pregabalin or morphine and gabapentin for neuropathic pain.Expert Opin Pharmacother. 2005; 6: 2535-2539
- Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin.J Pharmacol Exp Ther. 2000; 295: 1086-1093
- Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin.Neurosci Lett. 2000; 280: 107-110
- Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.Synapse. 2002; 45: 171-190
- Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.Neurology. 2003; 60: 1274-1283
- Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study.Epilepsia. 2005; 46: 1926-1936
- Fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum.J Pharm Sci. 1979; 68: 249-252
- Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices.Br J Pharmacol. 2000; 130: 900-906
- Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.Neuropharmacology. 2002; 42: 229-236
- Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures.Neurology. 2003; 60: 1631-1637
- Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.Pain. 2005; 115: 254-263
- Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent.Aust Vet J. 2005; 83: 602-608
- Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies.Eur J Pharmacol. 1993; 244: 303-309
Kugler AR, Robbins JL, Strand JC (2002). Pregabalin overview: a novel CNS-active compound with anticonvulsant activity. Poster presented at the annual meeting of the American Epilepsy Society, Seattle, WA, December 6–11.
- Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.Neurology. 2004; 63: 2104-2110
- Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices.Pain. 2001; 93: 191-196
- Calcium channel alpha(2)delta subunits-structure and Gabapentin binding.Mol Pharmacol. 2001; 59: 1243-1248
- Pregabalin in generalized anxiety disorder: a placebo-controlled trial.Am J Psychiatry. 2003; 160: 533-540
- Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy.Vet Rec. 2006; 159: 881-884
- Pharmacokinetics of pregabalin in subjects with various degrees of renal function.J Clin Pharmacol. 2003; 43: 277-283
- Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.J Pain. 2005; 6: 253-260
- Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.Arch Gen Psychiatry. 2005; 62: 1022-1030
- Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.Pain. 2004; 110: 628-638
- Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.Pain. 2004; 109: 26-35
Article info
Publication history
Accepted:
July 9,
2008
Received:
November 2,
2007
Identification
Copyright
© 2009 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia. Published by Elsevier Inc. All rights reserved.
